Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A powder for oral suspension, comprising:

a) non-dihydrate azithromycin; ~~and~~

b) an azithromycin form conversion stabilizing excipient which is a surface tension reducing excipient; and

c) an azithromycin form conversion enhancer, wherein

said surface tension reducing excipient is present in said powder for oral suspension in an amount sufficient to provide a surface tension of less than about 50 dynes/cm when an amount of said powder for oral suspension containing about 1 g of said non-dihydrate azithromycin is reconstituted with 10 ml of water.

2-8. (Canceled)

9. (Previously presented) The powder for oral suspension of 1 wherein the form conversion enhancer is selected from the group consisting of a flavoring and a volatile organic component.

10. (Original) The powder for oral suspension of Claim 9 wherein the flavoring is selected from the group consisting of vanilla, grape, cherry, banana, and mixtures thereof.

11. (Original) The powder for oral suspension of Claim 9 wherein the volatile organic component is selected from the group consisting of 3-methyl-butyl acetate and isoamyl isovalerate.

12-15. (Canceled)

16. (Currently amended) The powder for oral suspension of Claim 9 wherein the azithromycin ~~form conversion stabilizing excipient~~ surface tension reducing excipient is a non-ionic surfactant.

17. (Original) The powder for oral suspension of Claim 16 wherein the non-ionic surfactant is selected from the group consisting of a polysorbate, a nonylphenoxypolyoxyethylene, a polyoxyethylene ether and an octylphenolethylene oxide.

18-19. (Canceled)

20. (Previously presented) The powder for oral suspension of Claim 1 wherein the non-dihydrate azithromycin is selected from the group consisting of forms B, D, E, F, G, H, M, N, O, P, Q, R, and mixtures thereof.

21. (Original) The powder for oral suspension of Claim 20 further comprising a non-viscosifying sweetener.

22. (Original) The powder for oral suspension of Claim 21 wherein the non-viscosifying sweetener is selected from the group consisting of saccharin, aspartame, acesulfame potassium, thaumatin and monelin.

23. (Previously presented) The powder for oral suspension of Claim 1 wherein the non-dihydrate azithromycin comprises an ethanol solvate of azithromycin.

24. (Original) The powder for oral suspension of Claim 23 further comprising a non-viscosifying sweetener.

25. (Original) The powder for oral suspension of Claim 24 wherein the non-viscosifying sweetener is selected from the group consisting of saccharin, aspartame, acesulfame potassium, thaumatin and monelin.

26. (Previously presented) The powder for oral suspension of Claim 1 wherein the non-dihydrate azithromycin comprises an isopropanol solvate of azithromycin.

27. (Original) The powder for oral suspension of Claim 26 further composing a non-viscosifying sweetener.

28. (Original) The powder for oral suspension of Claim 27 wherein the non-viscosifying sweetener is selected from the group consisting of saccharin, aspartame, acesulfame, potassium, thaumatin and monelin.

Claims 29-78. (Canceled)

79. (New) The powder for oral suspension of Claim 9 wherein the azithromycin surface tension reducing excipient is anionic surfactant.

80. (New) The powder for oral suspension of Claim 79 wherein the anionic surfactant is selected from the group consisting of sodium lauryl sulfate and sodium dioctyl sulfosuccinate.